Based on the short-term price targets, what is the recommended investment strategy for CVKD at this juncture?

Based on the short-term price targets and the overall analysis, the recommended investment strategy for Cadrenal Therapeutics (CVKD) at this juncture is **cautious optimism with a medium-term focus**. Here's a detailed recommendation:

1. **Hold a Neutral Position**: With the average current price target from analysts being $32, which is a significant upside from the last closing price of $11.97, it suggests that the stock has potential for growth. However, given the recent volatility and the fact that the target price is still above the current price, it's prudent to hold a neutral position rather than a strong buy.
2. **Wait for Catalysts**: The stock's performance will likely be driven by upcoming catalysts such as:
- **FDA Updates**: The company is awaiting FDA discussions for pivotal Phase 3 trial refinement. Positive outcomes could significantly boost the stock.
- **Clinical Trial Progress**: The initiation of a Phase 3 trial evaluating tecarfarin versus warfarin for LVAD patients is a key event that could positively impact the stock.
- **Business Development**: The company's participation in conferences and investor meetings could lead to strategic partnerships or business development opportunities.
3. **Monitor Short-Term Indicators**: Keep a close eye on short-term indicators such as:
- **Market Sentiment**: Recent news sentiment scores indicate a positive outlook, which could support the stock's upward movement.
- **Technical Analysis**: The stock's recent performance shows a **15.42% jump** on June 30, 2025, which could indicate a strong buying pressure. However, the subsequent **-3.15% change** on July 1, 2025, suggests potential profit-taking or uncertainty.
4. **Risk Management**: Be mindful of potential risks such as:
- **Regulatory Hurdles**: The company faces FDA-related risks, and any delays could negatively impact the stock.
- **Financial Uncertainties**: Despite recent fundraising, the company's financials are still fragile, with a need for additional funding in 2025.
5. **Long-Term Perspective**: For investors with a medium-term to long-term horizon, the potential of tecarfarin's innovative therapy and the company's focus on rare cardiovascular indications make CVKD an attractive candidate. However, the short-term price targets should be used as a guide to manage risk and optimize entry and exit points.

In summary, while there is potential for growth, the current situation requires a cautious approach, focusing on managing risk while awaiting key catalysts that could drive the stock's performance forward.